MTG201 for Mesothelioma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Baylor College of Medicine, Houston, TX
Mesothelioma+2 More
MTG201 - Drug
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a virus may help treat malignant pleural mesothelioma.

See full description

Eligible Conditions

  • Mesothelioma
  • Malignant Pleural Mesothelioma (MPM)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Mesothelioma

Study Objectives

This trial is evaluating whether MTG201 will improve 1 primary outcome, 2 secondary outcomes, and 2 other outcomes in patients with Mesothelioma. Measurement will happen over the course of 3 months-2 years.

3 months-2 years
Objective response rate (ORR)
up to 2 years
Incidence of adverse events
change from baseline in liver transaminases
duration of response (DUR)
progression free survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Mesothelioma

Trial Design

1 Treatment Group

MTG201 plus Nivolumab
1 of 1
Experimental Treatment

This trial requires 12 total participants across 1 different treatment group

This trial involves a single treatment. MTG201 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

MTG201 plus NivolumabSingle arm, open-label, patients receive both MTG201 and nivolumab

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 2 years for reporting.

Closest Location

Baylor College of Medicine - Houston, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Mesothelioma or one of the other 2 conditions listed above. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Histologically confirmed locally advanced or metastatic pleural mesothelioma
Failed one prior treatment regimen including cisplatin-based chemotherapy
Eastern cooperative oncology group (ECOG) performance status; 0,1
Adequate organ function
Measurable disease per RECIST

Patient Q&A Section

How many people get mesothelioma a year in the United States?

"About 10,000 people in the US get mesothelioma and about 2,800 die from this disease annually. This disease is most likely to strike younger women who have been exposed to asbestos." - Anonymous Online Contributor

Unverified Answer

What are the signs of mesothelioma?

"The signs of mesothelioma are nonspecific and include fatigue, breathlessness, cough, fever, weight loss, anorexia and weight gain. There may also be a lump on the chest (coughing up blood). People may also have low-grade fever, fatigue, weight loss, shortness of breath and pain in the limbs and joints. Mesothelioma is usually a late-stage cancer and signs of the disease are seldom specific. The diagnosis is based on a history of exposure to asbestos, and X-ray or histological imaging, usually of the lungs. The prognosis of mesothelioma is poor, with a survival rate of less than 10% at 2 years." - Anonymous Online Contributor

Unverified Answer

What causes mesothelioma?

"A known etiology is observed in only about 20% of cases, indicating that it is not likely to play a critical role in malignant pleural mesothelioma (mesothelioma of the pleura). Although no firm explanation exists for the high rates of sarcomatous pleural mesothelioma, the fact that sarcomatous pleural mesothelioma is uncommon makes it likely to be the result of a complicated physiopathology, such as radiation, the asbestos or other fiber-containing materials, or other chemicals and/or infectious agents." - Anonymous Online Contributor

Unverified Answer

What are common treatments for mesothelioma?

"Many patients are diagnosed at an advanced stage of disease. Mesothelioma has a poor prognosis but may be managed using multimodality approaches, including radical surgery, chemotherapy, and radiotherapy." - Anonymous Online Contributor

Unverified Answer

Can mesothelioma be cured?

"Mesothelioma can be successfully managed by definitive surgical resection of the primary tumor. However, despite the use of adjuvant radiotherapy, mesothelioma is probably incurable and will eventually recur locally or systemically, with significant morbidity and mortality. Surgical resection remains the primary treatment modality of choice for this disease." - Anonymous Online Contributor

Unverified Answer

What is mesothelioma?

"Mesothelioma is a cancer that forms in the thin surface layer (the mesothelium) covering the visceral pleura, pericardium, and peritoneum. Symptoms are similar to those in epithelioma of the respiratory tract. In malignant mesothelioma, this cancer infiltrates and forms masses in the underlying underlying tissue." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for mesothelioma?

"This table shows the survival rate from several sources for a cancer of the pleura and peritoneum. It is possible to make a difference in survival for a cancer of the pleura when it is diagnosed earlier than its presentation as a tumor of the lung, when it spreads through the pleural space into the peritoneum, when it is of a more malignant type or when its size is bigger." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of mesothelioma?

"Results from a recent clinical trial showed that asbestos exposure has been the leading cause of mesothelioma. More information is needed to prove that environmental factors and genetic predisposition are involved. Nevertheless, the major impact of the asbestos fibers may be determined through an initial physical response and subsequent activation of intracellular events, culminating in the progressive transformation of normal human cells into mesothelioma\n" - Anonymous Online Contributor

Unverified Answer

Is mtg201 typically used in combination with any other treatments?

"MTG201 represents a promising new treatment option in preoperatively selected NSCLC patients with a PD-L1 antibody-positive and EGFR/K-ras wild-type genotype, currently assessed through a randomized phase II study in comparison to the combination regimen of paclitaxel, carboplatin and the anti-PD-1 nivolumab (the FDA granted accelerated approval in November 2015). A phase III study evaluating the superiority of combination regimen of MTG201 in comparison to paclitaxel, carboplatin and the anti PD-1 nivolumab in PD-L1 positive patients with EGFR/K-ras wild-type NSCLC is currently in progress." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets mesothelioma?

"The average age when patients develop mesothelioma is 71.05 years, with a sex distribution of 47.1% female and 52.9% male. Mesothelioma is more likely to occur in men, particularly those in the 80s. People over 85 years of age are also more likely to develop mesothelioma. Even though it mostly occurs in men, there are more malignant mesothelioma cases in women than in men. In general, early detection and treatment of benign mesothelioma are much easier than the diagnosis of malignant mesothelioma." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Mesothelioma by sharing your contact details with the study coordinator.